Eli Lilly Taps SeqWright to Use Roche NimbleGen and 454 Tools in Psychiatric Diseases Study
August 04, 2009
Eli Lilly Taps SeqWright to Use Roche NimbleGen and 454 Tools in Psychiatric Diseases Study
SeqWright CEO Fei Lu said this week that Lilly is one of an increasing number of pharma customers that have specifically requested sequence capture and sequencing services from the firm.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Array Firms Debut New Products to Cash in on 'Lucrative' Sequence-Capture Market
July 14, 2009 / BioArray News - Roche to Phase out Chip-Based Sequence Capture; Peptide Arrays 'Close' to Commercialization
October 2, 2012 / BioArray News - Sequencing Study Highlights Genetic Diversity in Southern Africa
February 17, 2010 / GenomeWeb Daily News - SeqWright, Eli Lilly to Use NimbleGen Capture, 454 Sequencing to Study Psychiatric Diseases
August 4, 2009 / In Sequence - SeqWright to Use 454, NimbleGen Tools in Eli Lilly Collaboration
July 30, 2009 / GenomeWeb Daily News